“Xeljanx is expected to overcome the limitation of rheumarthritis treatments”
As the first oral treatment for rheumarthritis, Xeljanz, has been launched, it is noticed that a new era has been opened in the rheumarthritis treatment market.
Pfizer Korea announced the launch of the oral rheumarthritis treatment, ‘Xeljanz (tofacitinib citrate)’ through its press meeting on th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
